Background {#s1}
==========

Herpes simplex virus encephalitis (HSVE) is the most common non-epidemic form of viral encephalitis in Western countries \[[@b1]\]. The infection usually affects the limbic structures resulting in seizures, personality change, memory dysfunction and focal neurological deficits. The diagnosis is made by positive HSV polymerase chain reaction (PCR) in the cerebrospinal fluid (CSF) and patients often respond to anti-viral treatment. The disease usually follows a monophasic course, but 14 -- 27% of the patients, often children, develop a recurrent encephalitic episode after successful treatment of the initial infection \[[@b2], [@b3], [@b4]\]. The pathogenesis of these relapses is heterogeneous ([Table 1](#Table1){ref-type="table"}): some cases represent true relapses of viral encephalitis, with positive HSV PCR in the CSF, new necrotic lesions in the MRI, and response to antiviral treatment. In these patients the relapsing symptoms represent a reactivation of the viral replication, or delayed symptoms of a persistent infection \[[@b2], [@b3], [@b4], [@b5], [@b6], [@b7], [@b8], [@b9], [@b10], [@b11], [@b12], [@b13], [@b14], [@b15]\]. In contrast, in a subset of relapsing patients the mechanisms that initiate the disorder are less clear. Children frequently have dyskinesia and choreoathetosis that typically develop 4 -- 6 weeks after the initial HSVE episode. In adult relapse cases, cognitive and psychiatric symptoms are more prominent and movement disorders have not been described \[[@b13], [@b16]\]. The CSF PCR for HSV is no longer positive, the MRI does not show new necrotic lesions, and symptoms do not respond to antiviral therapy. The exact etiology of this disorder has been unknown, but reports of patients who responded to immunotherapy suggested an immune-mediated pathogenic mechanism \[[@b2], [@b5], [@b13], [@b16], [@b17], [@b18], [@b19], [@b20], [@b21], [@b22], [@b23], [@b24], [@b25], [@b26], [@b27], [@b28], [@b29]\].

New evidence for NMDAR antibodies in post-HSVE {#s2}
==============================================

The hypothesis that a subgroup of non-infectious post-HSVE could have an immune-mediated pathogenesis has been recently supported by two studies discussed below, which indicate a link with anti-NMDAR encephalitis.

Anti-NMDAR encephalitis is a subacute, severe, but potentially treatable autoimmune encephalitis defined by the presence of IgG antibodies against cell surface epitopes of the NR1 subunit of the NMDAR. The resulting syndrome is characterized by prominent change of behavior, psychosis, memory deficits, seizures, abnormal movements, coma and autonomic dysfunction \[[@b30], [@b31], [@b32]\]. Some patients, mainly young women, harbor an underlying teratoma (usually in the ovary), in others the triggering factor for the NMDAR antibody production is unknown. Prodromal symptoms such as headache, fever, diarrhea or upper respiratory symptoms are frequently reported, leading to the hypothesis that an infectious disease could trigger the immunological disorder. However, routine serological and CSF studies in many patients, and several studies examining possible viral triggers did not identify a specific infectious agent \[[@b33], [@b34]\]. Recently, IgG NMDAR antibodies, identical to those associated with anti-NMDAR encephalitis (targeting the NR1 subunit of the NMDAR), were detected in 7% of patients with HSVE \[[@b35]\]. This study suggested that some atypical symptoms following HSVE, including prolonged abnormal movements (not responsive to viral therapies) or even episodes of post-HSVE (e.g., choreoathetosis post-HSVE) could be related to anti-NMDAR antibodies, representing in fact, anti-NMDAR encephalitis. Indeed, a recent pediatric series on anti-NMDAR encephalitis included a patient with post-HSVE choreoathetosis who had serum and CSF IgG antibodies against the NMDAR and responded to intensive immunotherapy \[[@b17]\]. Due to the retrospective nature of the study, serum and CSF from the time of the viral infection were not available and therefore the time course of antibody synthesis was unclear. However, in a more recent observation of post-HSVE in an adult, NMDAR antibodies could not be detected in serum or CSF at presentation of viral encephalitis, but were detected several weeks later when the patient developed relapsing neurological symptoms, including change of behavior, psychosis and memory deficits. Analysis of CSF for HSV was no longer positive, and the patient responded well to immunotherapy, along with a decrease of NMDAR antibody titers (Leypoldt et al., personal observation).

Possible pathogenetic mechanisms {#s3}
================================

These studies and observations offer new evidence of the occurrence of postviral autoimmunity against a known synaptic receptor. However, the question remains, which mechanisms specifically cause the breach of tolerance following HSVE. One possibility is molecular mimicry, whereby the viral protein sequence triggers an immune response that is misdirected against a structurally similar epitope present in the NMDAR. To date, there are no reports of a shared epitope sequence between HSV and NMDAR; future studies should address this possibility. Alternatively, the HSV-induced intense inflammatory response in limbic structures, usually accompanied by necrosis, could release and appropriately present abundantly expressed local NMDAR epitopes to the immunological system, breaking tolerance and initiating an autoimmune response. In this case, it would not be surprising that antibodies against other synaptic or neuronal cell surface antibodies might be identified in future studies. These could account for a wider spectrum of symptoms beyond the syndrome that frequently characterizes anti-NMDAR encephalitis \[[@b19]\].

Conclusion {#s4}
==========

In patients with relapsing symptoms of HSVE whose CSF PCR studies are negative for HSV routine diagnostic work-up should include screening for NMDAR antibodies in CSF and serum. Detection of these antibodies indicates that the disorder is anti-NMDAR encephalitis and should be treated with immunotherapy.
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Table 1.Post-HSVE: clinical features related to two pathogenic mechanisms.Infectious post-HSVEAutoimmune post-HSVEMedian age in years; (range)^a^5.25 (0.3 -- 71)3 (0.3 -- 67)Male : female^a^15 : 812 : 7Neurological symptoms^a^Focal neurological signs, seizures, behavioral abnormalities, disorientation; three cases with choreoathetosis \[[@b5], [@b6], [@b8]\]Choreoathetosis, ballism; one case with personality change, sleep disorder and bulimia \[[@b19]\];Time from initial HSV infection to relapsing symptomsVariable4 -- 6 weeksHSV PCR in CSFPositiveNegativeNew necrotic lesions on MRIYesNoResponse to anti-viral therapyYesNoEtiologyInfectiousAutoimmune[^1]

[^1]: ^a^Based on review of the literature; cases considered by the authors as infectious HSVE relapses (n = 28; age available in n = 26; gender available in n = 23) \[[@b2], [@b3], [@b4], [@b5], [@b6], [@b7], [@b8], [@b9], [@b10], [@b11], [@b12], [@b13], [@b14], [@b15]\] and autoimmune mediated HSVE relapses (n = 33; age available in n = 23; gender available in n = 19) \[[@b2], [@b5], [@b13], [@b16], [@b17], [@b18], [@b19], [@b20], [@b21], [@b22], [@b23], [@b24], [@b25], [@b26], [@b27], [@b28], [@b29]\].
